Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents

Schauer, Jenna; Buddhe, Sujatha; Colyer, Jessica; Sagiv, Eyal; Law, Yuk M.; Chikkabyrappa, Sathish; Portman, Michael A.

doi:10.1016/j.jpeds.2021.06.083

Cited by 60 publications

(82 citation statements)

References 8 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our initial search revealed 3092 records, of which 931 were excluded as duplicates. After screening the titles and, if necessary, full texts, eight published studies [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ] with 2852 children or adolescents and 28 ongoing clinical studies targeting to recruit a total of 122,442 participants were included. The study selection process is shown in detail in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Among the eight published studies included, two were RCTs [ 19 , 20 ], two were case series [ 21 , 22 ], and four were case reports [ 23 , 24 , 25 , 26 ]. Five studies were conducted in the United States, and one in China, France, and Israel each.…”

Section: Resultsmentioning

confidence: 99%

“…Most cases of myocarditis and pericarditis associated with the COVID-19 vaccine were mild, and mostly affected children were male. Schauer et al [ 26 ] estimated an incidence of myopericarditis of 0.008% in adolescents 16–17 years of age and 0.01% in those aged 12 through 15 years following the second dose.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review

Luo

Shen

et al. 2021

Vaccines

View full text Add to dashboard Cite

Aim: To identify the safety, immunogenicity, and protective efficacy of COVID-19 vaccines in children and adolescents. Methods: We conducted a systematic review of published studies and ongoing clinical studies related to the safety, immunogenicity, and efficacy of COVID-19 vaccine in children or adolescents (aged < 18 years). Databases including PubMed, Web of Science, WHO COVID-19 database, and China National Knowledge Infrastructure (CNKI) were searched on 23 July 2021. International Clinical Trials Registry Platform (ICTRP) was also searched to identify ongoing studies. Results: Eight published studies with a total of 2852 children and adolescents and 28 ongoing clinical studies were included. Of the eight published studies, two were RCTs, two case series, and four case reports. The investigated COVID-19 vaccines had good safety profiles in children and adolescents. Injection site pain, fatigue, headache, and chest pain were the most common adverse events. A limited number of cases of myocarditis and pericarditis were reported. The RCTs showed that the immune response to BNT162b2 in adolescents aged 12–15 years was non-inferior to that in young people aged 16–25 years, while with 3 μg CoronaVac injection the immune response was stronger than with 1.5 μg. The efficacy of BNT162b2 was 100% (95% CI: 75.3 to 100), based on one RCT. Of the 28 ongoing clinical studies, twenty-three were interventional studies. The interventional studies were being conducted in fifteen countries, among them, China (10, 43.5%) and United States(9, 39.1%) had the highest number of ongoing trials. BNT162b2 was the most commonly studied vaccine in the ongoing trials. Conclusion: Two COVID-19 vaccines have potential protective effects in children and adolescents, but awareness is needed to monitor possible adverse effects after injection. Clinical studies of the COVID-19 vaccination in children and adolescents with longer follow-up time, larger sample size, and a greater variety of vaccines are still urgently needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review

Luo

Shen

et al. 2021

Vaccines

View full text Add to dashboard Cite

show abstract

“…Case series 4 and several other reports suggest wide variability in clinical evaluation and treatment of adolescents 12-18 years of age with mRNA COVID-19 vaccine-associated myopericarditis (VAM) across institutions within the United States (US). 5 , 6 , 7 , 8 , 9 , 10 In order to better assess this variability, we conducted a cross-sectional survey of pediatric institutions across the US between July 9, 2021 and August 9, 2021. A secondary objective of this study was to determine the rate of serious, life-threatening complications (cardiopulmonary arrest requiring resuscitation, need for mechanical circulatory support [extracorporeal membrane oxygenation, Impella or ventricular assist device use], and death) in these adolescents.…”

mentioning

confidence: 99%

mRNA Coronavirus Disease 2019 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study

Kohli

Desai

Chowdhury³

et al. 2022

The Journal of Pediatrics

Self Cite

View full text Add to dashboard Cite

show abstract

“…More safety data are being collected by countries where adolescent vaccination is being rolled out. This surveillance has allowed the identification of several cases of perimyocarditis following immunization of young adults and adolescents with the BNT162b2 or the mRNA-1273 vaccine, particularly in young male adults and adolescents [128][129][130]. These cases were rare, with an estimate of between 1/10,000 and 1/100,000 vaccinees, and were mild and self-limited.…”

Section: Vaccination Of Childrenmentioning

confidence: 99%

Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention

et al. 2021

View full text Add to dashboard Cite

Children are unique in the context of the COVID-19 pandemic. Overall, SARS-CoV-2 has a lower medical impact in children as compared to adults. A higher proportion of children than adults remain asymptomatic following SARS-CoV-2 infection and severe disease and death are also less common. This relative resistance contrasts with the high susceptibility of children to other respiratory tract infections. The mechanisms involved remain incompletely understood but could include the rapid development of a robust innate immune response. On the other hand, children develop a unique and severe complication, named multisystem inflammatory syndrome in children, several weeks after the onset of symptoms. Although children play an important role in the transmission of many pathogens, their contribution to the transmission of SARS-CoV-2 appears lower than that of adults. These unique aspects of COVID-19 in children must be considered in the benefit–risk analysis of vaccination. Several COVID-19 vaccines have been authorized for emergency use in adolescents and clinical studies are ongoing in children. As the vaccination of adolescents is rolled out in several countries, we shall learn about the impact of this strategy on the health of children and on transmission within communities.

show abstract

Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents

Cited by 60 publications

References 8 publications

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review

mRNA Coronavirus Disease 2019 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study

Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention

Contact Info

Product

Resources

About